Carl Dambkowski Sells 5,110 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 5,110 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $39.80, for a total value of $203,378.00. Following the transaction, the insider directly owned 284,733 shares in the company, valued at approximately $11,332,373.40. The trade was a 1.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, September 3rd, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The stock was sold at an average price of $37.87, for a total value of $103,195.75.
• On Wednesday, August 6th, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The stock was sold at an average price of $37.78, for a total value of $102,950.50.

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE opened at $39.88 on Friday. The stock’s 50-day moving average is $37.59 and its two-hundred day moving average is $38.18. Apogee Therapeutics Inc. has a 1-year low of $26.20 and a 1-year high of $63.50. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -9.66 and a beta of 1.43.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, August 11th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.10). Equities research analysts anticipate that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

APGE has been the topic of several recent research reports. BTIG Research upped their price target on Apogee Therapeutics from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, July 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apogee Therapeutics in a report on Saturday, September 27th. Wedbush reiterated an “outperform” rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a report on Monday, August 11th. Royal Bank Of Canada began coverage on Apogee Therapeutics in a report on Thursday, September 25th. They issued an “outperform” rating and a $60.00 price objective on the stock. Finally, Guggenheim reiterated a “buy” rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a report on Wednesday, July 2nd. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $92.63.

Institutional Trading of Apogee Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. acquired a new stake in Apogee Therapeutics during the 4th quarter worth approximately $259,000. Rhumbline Advisers lifted its holdings in shares of Apogee Therapeutics by 3.2% in the 1st quarter. Rhumbline Advisers now owns 54,385 shares of the company’s stock valued at $2,032,000 after buying an additional 1,665 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Apogee Therapeutics by 93.3% in the 1st quarter. Bank of New York Mellon Corp now owns 214,231 shares of the company’s stock valued at $8,004,000 after buying an additional 103,404 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Apogee Therapeutics by 4.4% in the 1st quarter. Victory Capital Management Inc. now owns 232,983 shares of the company’s stock valued at $8,704,000 after buying an additional 9,921 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Apogee Therapeutics by 3,560.1% in the 1st quarter. GAMMA Investing LLC now owns 5,417 shares of the company’s stock valued at $202,000 after buying an additional 5,269 shares during the period. 79.04% of the stock is owned by institutional investors and hedge funds.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.